Investigational Drug Information for Volasertib
✉ Email this page to a colleague
What is the drug development status for Volasertib?
Volasertib is an investigational drug.
There have been 25 clinical trials for Volasertib.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 29th 2013.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, Acute, and Leukemia, Myeloid. The leading clinical trial sponsors are Boehringer Ingelheim, National Comprehensive Cancer Network, and Anne Beaven, MD.
Summary for Volasertib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 397 |
| WIPO Patent Applications | 268 |
| Japanese Patent Applications | 29 |
| Clinical Trial Progress | Phase 3 (2013-01-29) |
| Vendors | 63 |
Recent Clinical Trials for Volasertib
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia | University of Alberta | Phase 1 |
| A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy Failed | Boehringer Ingelheim | Phase 1 |
| Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL | Boehringer Ingelheim | Phase 1 |
Clinical Trial Summary for Volasertib
Top disease conditions for Volasertib
Top clinical trial sponsors for Volasertib
US Patents for Volasertib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
